These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35385018)

  • 1. [COVID-19 vaccine safety].
    Chaparro Mérida NA; Moreno Samper D; Lacato AOF
    Rev Peru Med Exp Salud Publica; 2021; 38(4):634-642. PubMed ID: 35385018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2-related and Covid-19 vaccine-induced thromboembolic events: A comparative review.
    Afshar ZM; Barary M; Babazadeh A; Hosseinzadeh R; Alijanpour A; Miri SR; Sio TT; Sullman MJM; Carson-Chahhoud K; Langer F; Ebrahimpour S
    Rev Med Virol; 2022 Jul; 32(4):e2327. PubMed ID: 35112763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine safety - is the SARS-CoV-2 vaccine any different?
    Tau N; Yahav D; Shepshelovich D
    Hum Vaccin Immunother; 2021 May; 17(5):1322-1325. PubMed ID: 33270474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the safety and efficacy of current COVID-19 vaccines.
    Huang Z; Su Y; Zhang T; Xia N
    Front Med; 2022 Feb; 16(1):39-55. PubMed ID: 35122210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines - where do we stand?
    Aliasin MM; Yazdanpanah N; Rezaei N
    Rev Neurosci; 2022 Oct; 33(7):721-743. PubMed ID: 35334195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Vaccines: Where Did We Stand at the End of 2023?
    Lundstrom K
    Viruses; 2024 Jan; 16(2):. PubMed ID: 38399979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.
    Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M
    Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Safety of COVID-19 Vaccines: A Primer.
    Petousis-Harris H
    Drug Saf; 2020 Dec; 43(12):1205-1210. PubMed ID: 32997318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocarditis Following COVID-19 Vaccine Use: Can It Play a Role for Conditioning Immunization Schedules?
    Esposito S; Caminiti C; Giordano R; Argentiero A; Ramundo G; Principi N
    Front Immunol; 2022; 13():915580. PubMed ID: 35833128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status of COVID-19 vaccine development.
    Taxt AM; Grødeland G; Lind A; Müller F
    Tidsskr Nor Laegeforen; 2020 Sep; 140(13):. PubMed ID: 32998488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.